The biotechnology sector is leading the US IPO market in 2026, significantly outperforming AI firms like Anthropic. With biotech IPOs achieving a 55% average return, they stand in stark contrast to the broader market, which has seen a 4.4% decline.
This surge in biotech is reshaping investor sentiment, particularly regarding AI IPOs. Anthropic, for instance, has seen a slight decline in the projected likelihood of its IPO by September 30, 2026, now estimated at 5.5%. This shift suggests that the strong performance of biotech may be diverting attention and resources away from AI ventures, despite their substantial valuations and potential.
As the biotech sector continues to capture market interest, the outlook for AI companies could become increasingly challenging. The competitive landscape set by biotech firms may hinder the momentum that AI IPOs, such as Anthropic’s, need to thrive.
Looking ahead, market participants will be vigilant for any updates regarding Anthropic’s IPO plans, as announcements or regulatory changes could significantly alter current expectations. The evolving dynamics between biotech and AI sectors will be crucial in shaping the future landscape of IPOs.